245 related articles for article (PubMed ID: 29491412)
1. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
[TBL] [Abstract][Full Text] [Related]
2. HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
Lin X; Huang X; Uziel T; Hessler P; Albert DH; Roberts-Rapp LA; McDaniel KF; Kati WM; Shen Y
Mol Cancer Ther; 2017 Feb; 16(2):388-396. PubMed ID: 27903752
[TBL] [Abstract][Full Text] [Related]
3. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
[TBL] [Abstract][Full Text] [Related]
4. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
5. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
[No Abstract] [Full Text] [Related]
6. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.
Devaraj SG; Fiskus W; Shah B; Qi J; Sun B; Iyer SP; Sharma S; Bradner JE; Bhalla KN
Leukemia; 2016 Feb; 30(2):504-8. PubMed ID: 26148704
[No Abstract] [Full Text] [Related]
7. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
8. The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.
Liu PY; Sokolowski N; Guo ST; Siddiqi F; Atmadibrata B; Telfer TJ; Sun Y; Zhang L; Yu D; Mccarroll J; Liu B; Yang RH; Guo XY; Tee AE; Itoh K; Wang J; Kavallaris M; Haber M; Norris MD; Cheung BB; Byrne JA; Ziegler DS; Marshall GM; Dinger ME; Codd R; Zhang XD; Liu T
Oncotarget; 2016 Nov; 7(48):79217-79232. PubMed ID: 27764794
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.
Tontsch-Grunt U; Rudolph D; Waizenegger I; Baum A; Gerlach D; Engelhardt H; Wurm M; Savarese F; Schweifer N; Kraut N
Cancer Lett; 2018 May; 421():112-120. PubMed ID: 29454094
[TBL] [Abstract][Full Text] [Related]
10. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
Bernasconi E; Gaudio E; Lejeune P; Tarantelli C; Cascione L; Kwee I; Spriano F; Rinaldi A; Mensah AA; Chung E; Stathis A; Siegel S; Schmees N; Ocker M; Zucca E; Haendler B; Bertoni F
Br J Haematol; 2017 Sep; 178(6):936-948. PubMed ID: 28653353
[TBL] [Abstract][Full Text] [Related]
12. BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.
Winter GE; Mayer A; Buckley DL; Erb MA; Roderick JE; Vittori S; Reyes JM; di Iulio J; Souza A; Ott CJ; Roberts JM; Zeid R; Scott TG; Paulk J; Lachance K; Olson CM; Dastjerdi S; Bauer S; Lin CY; Gray NS; Kelliher MA; Churchman LS; Bradner JE
Mol Cell; 2017 Jul; 67(1):5-18.e19. PubMed ID: 28673542
[TBL] [Abstract][Full Text] [Related]
13. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
[TBL] [Abstract][Full Text] [Related]
15. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.
Rahaman MH; Yu Y; Zhong L; Adams J; Lam F; Li P; Noll B; Milne R; Peng J; Wang S
Invest New Drugs; 2019 Aug; 37(4):625-635. PubMed ID: 30194564
[TBL] [Abstract][Full Text] [Related]
16. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
[TBL] [Abstract][Full Text] [Related]
17. High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.
Zhao Y; Liu Q; Acharya P; Stengel KR; Sheng Q; Zhou X; Kwak H; Fischer MA; Bradner JE; Strickland SA; Mohan SR; Savona MR; Venters BJ; Zhou MM; Lis JT; Hiebert SW
Cell Rep; 2016 Aug; 16(7):2003-16. PubMed ID: 27498870
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
20. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
